Norge - norsk - Statens legemiddelverk

merz pharmaceuticals gmbh - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning - 100 e

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklide bildebehandling - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Den europeiske union - norsk - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Den europeiske union - norsk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Den europeiske union - norsk - EMA (European Medicines Agency)

teva pharma b.v. - kapecitabin - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastiske midler - capecitabine teva er indisert for adjuverende behandling av pasienter etter operasjon av fase iii (dukes 'stadium c) tykktarmskreft. capecitabine teva er angitt for behandling av metastatisk kolorektal kreft. capecitabine teva er indikert for første‑linje behandling av avansert magekreft i kombinasjon med et platinum‑basert diett. capecitabine teva i kombinasjon med docetaxel er indisert for behandling av pasienter med lokalt avansert eller metastatisk brystkreft etter svikt av cytotoksisk kjemoterapi. tidligere behandling bør ha inkludert en antracyklin. capecitabine teva er også indisert som monoterapi for behandling av pasienter med lokalt avansert eller metastatisk brystkreft etter svikt av taxanes og en anthracycline inneholder kjemoterapi diett eller for hvem videre anthracycline terapi er ikke angitt.

Den europeiske union - norsk - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Norge - norsk - Statens legemiddelverk

stragen nordic a/s - ceftazidimpentahydrat - pulver til injeksjonsvæske, oppløsning - 1000 mg

Norge - norsk - Statens legemiddelverk

stragen nordic a/s - ceftazidimpentahydrat - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g

Norge - norsk - Statens legemiddelverk

medac gesellschaft für klinische spezialpräparate mbh - vinorelbintartrat - konsentrat til infusjonsvæske, oppløsning - 10 mg/ ml

Norge - norsk - Statens legemiddelverk

viatris limited - atovakvon / proguanilhydroklorid - tablett, filmdrasjert - 250 mg / 100 mg